Web Date: October 12, 2010
Exelixis Expands Collaboration With Bristol-Myers Squibb
Following the termination of a codevelopment pact with Bristol-Myers Squibb (BMS) on XL184, the most advanced drug in its pipeline, Exelixis announced two new agreements with BMS on Oct 11. Exelixis and BMS could not agree on clinical development of XL 184, which is in Phase III trials for thyroid cancer and Phase II trials for glioblastoma (C&EN, June 28, page 22).
In the new deals, the South . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society